Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels
Sponsor: Qualia Life Sciences
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.
Official title: Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels: A Randomized, Double-Blind, Placebo-Controlled Three-Arm Trial
Key Details
Gender
All
Age Range
35 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
180
Start Date
2025-10-13
Completion Date
2025-12-15
Last Updated
2025-08-20
Healthy Volunteers
Yes
Conditions
Interventions
Qualia NAD⁺ version 1
Qualia NAD+ version 1 manufactured by Qualia Life Sciences
Qualia NAD⁺ version 2
Qualia NAD+ version 2 manufactured by Qualia Life Sciences
Placebo
Rice Flour
Locations (1)
Qualia Life Sciences
Carlsbad, California, United States